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Abstract  1 
Background- Postpartum haemorrhage (PPH) remains a leading cause of maternal morbidity 2 
and mortality worldwide. Delay in diagnosis and care for PPH has been reported. The 3 
inaccuracy of visual estimation of postpartum blood loss has been demonstrated.  4 
Objectives- To evaluate the effectiveness of the systematic use of a transparent plastic 5 
collector bag for measurement of postpartum blood loss after vaginal delivery in reducing the 6 
incidence of severe PPH  7 
Design- A cluster randomised trial 8 
Setting- Thirteen European countries 9 
Participants-78 maternity units and 25381 women who had a vaginal delivery 10 
Interventions- Maternity units were randomly assigned to systematically use a collector bag 11 
(intervention group), or to continue to visually assess postpartum blood loss after vaginal 12 
delivery (control group) 13 
Main outcome measures- The primary outcome was the incidence of severe PPH in vaginal 14 
deliveries, defined as a composite of one or more of the following events: blood transfusion, 15 
intravenous plasma expansion, arterial embolisation, surgical procedure, admission to 16 
intensive care unit, treatment with recombinant factor VII, or death. 17 
Results- The incidence of severe PPH was 189 out of 11037 of vaginal deliveries (1.71%) in 18 
the intervention group compared to 295 out of 14344 in the control group (2.06%). The 19 
difference was not statistically significant either in individual level analysis (adjusted odds 20 
ratio 0.82; 95% CI 0.26 to 2.53) or in cluster level analysis (difference in weighted mean rate 21 
adjusted for baseline rate 0.16%; 95 % CI -0.69% to 1.02%).   22 
Conclusion- The use of a collector bag after vaginal delivery did not reduce the rate of severe 23 
PPH as compared to visual estimation of postpartum blood loss.  24 
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Trial registration: International Standard Randomised Controlled Trial Number (ISRCTN) 1 
66197422. 2 
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Introduction  1 
Worldwide, postpartum haemorrhage (PPH) remains one of the leading causes of maternal 2 
mortality
1
 and the main component of severe morbidity
2-5
, jeopardizing the  woman’s fertility, 3 
exposing her to risks of transfusion and intensive care, and incurring costs. From reports in 4 
developed countries, about one percent of deliveries are associated with severe PPH
3-6
.  5 
Decreasing the prevalence of severe PPH remains challenging. This appears all the more 6 
important  given the recent increase in the incidence of PPH reported in several developed 7 
countries
2, 7, 8
. Individual risk factors have been described but they poorly predict the 8 
occurrence of PPH 
9, 10
. Interest has focused on care-processes as they are potentially 9 
amenable to change. Studies of maternal deaths show that most deaths due to PPH involve 10 
delayed and substandard care in the diagnosis and management of haemorrhage
11-13
. Similar 11 
findings were drawn from a population-based study of severe non-lethal PPH
14
.   12 
Delay in diagnosis and treatment of PPH may result from an underestimation of blood loss at 13 
delivery. Assessment of post-partum blood loss, particularly following vaginal birth, is 14 
recognised as difficult. Many studies demonstrate that visual estimates of peripartum blood 15 
loss are frequently inaccurate
15-21
, showing an overestimation of blood loss at low volumes 16 
and an underestimation at larger volumes, the magnitude of underestimation typically 17 
increasing with the volume of haemorrhage. 18 
The hypothesis of this study was that if blood loss is monitored and objectively measured by 19 
collection in a transparent plastic bag, rather than being visually assessed, care-giver response 20 
will be triggered more rapidly when excessive blood loss occurs. Specifically when bleeding 21 
is excessive but before haemorrhage has become catastrophic, appropriate management will 22 
take place without delay, so reducing the incidence of severe PPH. A preliminary study shows 23 
that a plastic collector bag constitutes a simple instrument to diagnose haemorrhage in the 24 
delivery room
22
. However, the impact of its use on PPH-related health outcomes has never 25 
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been tested. Despite lacking evidence, the bag is routinely used in a significant proportion of 1 
maternity units in Belgium, France, Italy, and Portugal (Euphrates survey
23
, unpublished data). 2 
The objective of this trial was to evaluate the effectiveness of the systematic use of a 3 
transparent plastic collector bag for measurement of postpartum blood loss after vaginal 4 
delivery in reducing the incidence of severe PPH.  5 
 6 
Methods   7 
Trial design  8 
A cluster-randomised design with maternity unit was the unit of randomization. Given the 9 
logistics of clinical practice on the delivery suite, contamination appeared to be inevitable in 10 
an individual-patient randomised trial setting.  11 
Setting 12 
The sites selected for the trial comprised 78 maternity units in 13 European countries (see 13 
Table1). 14 
Participants  15 
Maternity units 16 
Maternity units were eligible if they had more than 200 vaginal deliveries annually (excluding 17 
water births), and no previous policy of routine use of collector bags. In addition, to ensure 18 
that the standard of care for management of the third stage of labour was similar across all 19 
participating units, they had to comply with the EUPHRATES consensus statement on the 20 
prevention and management of PPH
24
; a minimum standard, not a detailed guideline. 21 
Women 22 
In all maternity units of participating countries (except Denmark), all women undergoing a 23 
vaginal delivery during the study period were included. In Denmark, enrolment into the study 24 
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in each maternity unit was midwife-dependant; if a midwife agreed to participate, all his/her 1 
vaginal deliveries were included. 2 
 3 
Randomization 4 
The random allocation was produced centrally by the National Perinatal Epidemiology Unit in 5 
Oxford, UK. A stratified design was used to ensure that the two arms of the trial were as 6 
similar as possible at baseline with respect to the stratification factors (i) country and (ii) size 7 
of maternity unit (median split within country).  8 
Maternity units were randomly allocated to either systematically use a collector bag after 9 
vaginal delivery (intervention arm), or not use the bag (control group).  10 
 11 
Intervention 12 
The trial was implemented between January 2006 and May 2007, depending on the country. 13 
Prior to participation, each centre was visited by the national coordinator. At the visit, staff 14 
were reminded of the EUPHRATES consensus statement on the prevention and management 15 
of PPH and familiarised with the processes and the data collection instrument.  16 
In the intervention group, a second visit from the national coordinator took place after 17 
randomisation, during which, use of the collector bag was explained to birth attendants with 18 
standard written instructions and a training video aid. The bag was to be placed under the 19 
pelvis of the mother as soon as the baby was born and before delivery of the placenta.  It was 20 
transparent and graduated, allowing continuous monitoring of blood loss. It did not require 21 
sterilization and could be used in dorsal, lateral or lithotomy positions. Women delivering 22 
standing or crouching could be offered the opportunity to lie down for the third stage, 23 
allowing the bag to be placed under their pelvis. The bag was to be left under the woman’s 24 
buttocks until the birth attendant was no longer concerned about blood loss e.g. when the 25 
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sanitary towel was applied to the vulva. Bags were purchased centrally and provided to each 1 
cluster in the intervention arm.  2 
In the control group, no collector bag was used, postpartum blood loss being visually assessed. 3 
During the study period, use of collector devices was monitored to assess compliance with 4 
allocation. 5 
 6 
Outcomes 7 
The primary outcome for the trial was the incidence of severe PPH following vaginal 8 
deliveries, defined as a composite of all women who experienced one or more of the 9 
following: blood transfusion, intravenous plasma expansion, arterial embolisation, surgical 10 
procedure, admission to intensive care unit, treatment with recombinant factor VII and death. 11 
Secondary outcomes were each of the components of the primary outcome, manual removal 12 
of the placenta and administration of prostaglandins after delivery. 13 
 14 
Data collection 15 
Each participating centre was asked to collect data from all women undergoing a vaginal 16 
delivery for a period of 4 months.  17 
Data were collected during two time intervals: a 1-month period pre-randomisation (baseline 18 
period), and a 3-month period beginning immediately following randomisation in the control 19 
group (trial period).  In the intervention group, the 3-month period of data collection followed 20 
a 2-week training period during which the unit started using the collector bag on women 21 
undergoing vaginal delivery. 22 
Data were collected using a form filled in by the birth attendants for each vaginal delivery,  23 
and included information on the woman’s age, induction of labour, mode of delivery, number 24 
of babies and birth weight, prophylactic uterotonics, and outcome data. Additionally, a second 25 
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form was used for deliveries where severe PPH occurred, collecting detailed information 1 
regarding delivery and PPH management. This form was used to cross-check criteria for the 2 
primary outcome. 3 
 4 
Sample size  5 
Sample size calculation took into account the cluster-randomised design; the intracluster 6 
correlation coefficient was estimated to be 0.01. Assuming an event rate for the primary 7 
outcome of 2.5% in the control group, in order to detect a decrease in the event rate to 1.5% (a 8 
40% relative risk reduction) with 80% power, a 2-sided significance level of 5% and an 9 
average cluster size of 300 women, 82 clusters (41 in each arm of the trial) were required
25
. 10 
 11 
Statistical analysis  12 
Participants/maternity units were analysed in the groups to which they were assigned 13 
regardless of the management received by individual women or deviation from the protocol.  14 
Baseline characteristics of maternity units and individual women were summarized with 15 
counts (percentages) for categorical variables, mean (standard deviation [SD]) for normally 16 
distributed continuous variables, or median (interquartile [IQR]) for other continuous 17 
variables. Comparative statistical analysis was performed at both individual and cluster level 18 
and took into account the effect of clustering. All statistical tests were two-sided (5% 19 
significance level) and not adjusted for multiple comparisons. Statistical analyses were 20 
performed using SPSS version 17 (SPSS) and Stata v10.0 software (Stata Corporation, 21 
College Station, Texas, USA). 22 
Individual woman level analysis - primary and secondary outcomes were compared between 23 
the two study groups both unadjusted and adjusted for the effect of clustering. In order to 24 
determine the magnitude and direction of any differences in outcomes between the two 25 
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groups, crude odds ratios and 95% confidence intervals were calculated. Furthermore, logistic 1 
regression was used to adjust for clustering and key prognostic factors. The cluster 2 
randomised design imparts a data structure that facilitates the calculation of a valid 3 
intracluster correlation coefficient, ρ. 4 
Cluster level analysis was only performed on the primary outcome. Some hospitals 5 
contributed fewer events than others, and some recruited fewer women. We allowed these 6 
hospitals to have less effect on the treatment estimate by weighting the analysis based on the 7 
precision, i.e. calculating the weighted mean difference for the treatment comparison. A 8 
weighted linear regression model was used to test the effect of the intervention on the rate of 9 
severe PPH during the trial period, adjusting for the baseline rate, expressed as the weighted 10 
mean difference (plus 95% confidence interval). 11 
 12 
Ethical aspects 13 
Ethics approval was obtained in each country from relevant local or national research ethics 14 
committees. Consent to participate was taken from the maternity units. Because the procedure 15 
being tested was not invasive or different from current clinical practice, and because outcome 16 
data were routinely collected at maternity units and anonymously transmitted, no individual 17 
consent was sought. 18 
 19 
Role of the funding source  20 
The project was funded by the European Union (EU) under Framework 5 (contract QLG4-21 
CT-2001-01352). EU had no role in the design, management, data collection, analyses, or 22 
interpretation of the data. EU had no role in the writing of the manuscript or in the decision to 23 
submit for publication.  24 
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 1 
Results 2 
Figure 1 shows the flow of maternity units and women through the study.  Of the 84 maternity 3 
units meeting the inclusion criteria, two maternity units declined to participate before 4 
allocation. Forty one maternity units were randomised to the intervention group and 41 to the 5 
control group. Two maternity units in each group opted out before receiving notification of 6 
allocation because they lacked the necessary resources. Thirty-nine maternity units in each 7 
group completed the trial. Table 1 shows the number of participating maternity units and 8 
women included in each country.  9 
One maternity unit did not collect baseline data in the intervention group. Deviating from the 10 
protocol, the majority of maternity units (31 of 39) continued collecting data during the 2-11 
week training period in the intervention arm. In these units, trial data collection started after 12 
the first month of baseline data collection. Four units in the control group collected trial data 13 
for more than 3 months (up to 5 months). Only the 3-month period of data collection specified 14 
in the protocol was considered for all units. In some Austrian hospitals, the number of women 15 
included was low, given the total expected number of deliveries. The national coordinator 16 
confirmed that the missing data were all caesarean deliveries, and that in some hospitals the 17 
caesarean rate was very high. Nevertheless, sensitivity analyses were performed, and showed 18 
that excluding these hospitals or even the entire Austrian data set did not influence the results.  19 
 20 
Characteristics of maternity units and women 21 
Baseline data were collected for 4937 in the intervention group and 4758 vaginal deliveries in 22 
the control group and characteristics of maternity units and women (Table 2) were broadly 23 
similar in the two groups for all factors, except for manual removal of the placenta and 24 
prophylactic uterotonics, which were more common among women in the intervention group.  25 
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Primary outcome  1 
Individual level analysis 2 
 A total of 25381 women were included in the analysis (11037 in the intervention group and 3 
14344 in the control group). The greater number of women in the control group was due to a 4 
larger median cluster size (241 and 284 in the intervention and control groups, respectively)..  5 
The incidence of severe PPH was 189 out of 11037 of vaginal deliveries (1.71%) in the 6 
intervention group compared to 295 out of 14344 in the control group (2.06%). The difference 7 
was not statistically significant (Table 3). The crude odds ratio for the effect of the 8 
intervention was 0.83 (95% CI, 0.69 to 1.00). The odds ratio adjusted for clustering was 0.83 9 
(95% CI, 0.27 to 2.60); after further adjustment for age, prophylactic uterotonics in the third 10 
stage, mode of delivery and birth weight, the odds ratio was 0.82 (95% CI, 0.26 to 2.53).  11 
Sensitivity analyses were conducted to test the robustness of this result excluding units 12 
deviating from the protocol, and also by country, and by baseline rate of severe PPH (median 13 
split by country); these analyses provided similar results. 14 
Cluster level analysis 15 
The weighted mean severe PPH rate was  1.71% (SD 2.51) in the intervention group and 16 
2.06% (SD 3.52) in the control group. The intracluster correlation coefficient for severe PPH 17 
was 0.023. There was no significant difference in the rate of severe PPH between the two 18 
groups (weighted mean difference -0.34%, (-2.56% to 1.87%); p=0.75). Adjusting for the 19 
baseline rate of severe PPH resulted in a slight change in this result (adjusted weighted mean 20 
difference 0.16%, (-0.69% to 1.02%); p=0.70). Rates of severe PPH in the baseline and trial 21 
periods for each maternity unit were heterogeneous across units in different countries (Figure 22 
2).  23 
Figure 3 shows the difference in baseline and trial rates of severe PPH for each unit in the 24 
intervention group, according to the compliance of bag usage. There was no relationship 25 
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between the difference in severe PPH rates (baseline and trial) and the actual proportion of 1 
bag use. The analysis of the intervention effect on the primary outcome, including in the 2 
intervention arm only maternity units where the bag was used in at least 50% of vaginal 3 
deliveries, showed no significant difference between the two groups (individual level analysis 4 
adjusting for cluster and individual characteristics; adjusted OR 0.59, 95% CI (0.23-1.53)). 5 
 6 
Secondary outcomes (individual level analysis)  7 
Analyses were performed to test the effect of the intervention on the main components of the 8 
primary outcome (Table 3). The proportion of blood transfusion, surgical procedure or 9 
embolisation and of manual removal of placenta, did not substantially differ between the 10 
intervention and control groups, whether after adjusting for cluster or after further adjusting 11 
for other prognostic factors. There were no maternal deaths. 12 
The proportions of receipt of intravenous plasma expanders and of prostaglandins use were 13 
different between intervention and control groups, but the differences were not significant 14 
after adjusting for clustering effect. 15 
 16 
Discussion 17 
Strengths and limitations of study 18 
In this cluster randomised trial conducted on 25381 vaginal deliveries in 78 maternity units of 19 
13 European countries, the systematic use of a collector bag after vaginal delivery did not 20 
modify the rate of severe forms of postpartum haemorrhage.  There was no evidence of 21 
heterogeneity, the results not differing according to country or size of hospital.   22 
This trial provides new results on an unexplored although controversial aspect of care in the third 23 
stage of labour.  Although objective measurement has been shown to increase the accuracy of 24 
postpartum blood loss assessment compared to visual estimation15-21, the routine use of a collector 25 
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bag is not associated with a significant decrease in severe PPH. This result constitutes an important 1 
contribution to the on-going debate on strategies to improve the care of women with PPH and 2 
decrease the incidence of severe cases.  3 
Additionally, the cluster-randomised design, the large number of clusters and their diversity 4 
provide good external validity to this trial. 5 
There were small deviations from the protocol for data collection, but sensitivity analyses showed 6 
that none of these changed the internal validity of the trial.     7 
There was large heterogeneity of baseline rates for the severe event between units (0 to 13.4 %).  In 8 
theory, such a variation should be an asset, and reflect a broad range of levels of risk in the 9 
participating maternity units.  However, because these differences were strongly related to the 10 
country, there remains some concern regarding the criteria in use for the management of PPH in 11 
different parts of Europe.  Again sensitivity analysis showed that this aspect did not alter the 12 
results.   13 
There was some heterogeneity in baseline data between the intervention and control groups.  14 
Heterogeneity in PPH-related practices and PPH rates has been reported across maternity 15 
units in Europe, both between and within countries
4, 23
.  Although randomization is expected 16 
to balance these differences between the two arms, the number of units randomized, although 17 
large for a cluster RCT, makes residual imbalance possible although probably very slight. 18 
However, analyses were adjusted for the main determinants of PPH (individual level analysis), 19 
and baseline rate of severe PPH (cluster-level analysis); in addition, sensitivity analysis 20 
indicated that the absence of significant impact of the intervention was similar whether the 21 
maternity units had high or low baseline rate of severe PPH. In consequence, any perceived or 22 
real imbalance in these characteristics should have little or no impact on the findings.  23 
 24 
Hypotheses for the results  25 
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Different mechanisms may explain the absence of difference in the rates of severe PPH between 1 
maternity units which used the bag and those where blood loss was visually assessed.  2 
This may be due to a lack of compliance to the intervention. However, the persistent absence 3 
of difference between the 2 groups when the analysis was restricted to the units where the bag 4 
was used in a high proportion of deliveries suggests this is unlikely.  5 
One potential reason for the apparent ineffectiveness of the intervention might be that the 6 
bags were actually not used correctly; in particular, there might be concern that the bags were 7 
covered most of the time and thus could not be viewed. However, because detailed oral and 8 
written instructions were provided and the training video clearly showed the care giver 9 
watching the bag and the graduations, such misuse is unlikely to explain the observed lack of 10 
effect. 11 
Participation in the study may indicate a particular interest in the management of PPH so that 12 
existing management had little room for improvement. However, the variety of baseline rates 13 
of severe PPH in these units makes such a selection process unlikely. 14 
It may be hypothesized that the intervention has a double effect, in two opposite directions: 15 
increasing the rate of ascertainment through increased vigilance and decreasing the prevalence rate 16 
through timely management of excessive bleeding.  If these two components were of the same 17 
order of magnitude, the global effect would be no effect.  However, if this explanation was 18 
realistic, one would expect different size of effects with different baseline rates and/or different 19 
degrees of compliance.  None of this occurred, making it unlikely that a benefit of the intervention 20 
in terms of decreased severe outcome was balanced by an equivalent increase in ascertainment.  In 21 
fact the intervention appeared to increase PPH rates, reflecting possibly, that the intervention was 22 
more effective on improving ascertainment than on changing practice. 23 
A concomitant effect in the control group may also have contributed to the absence of 24 
difference between the two arms. Contamination of the intervention to control units is 25 
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unlikely since participating units were not in contact, and no use of bags was reported in any 1 
control unit.  Participation in a research study, independently of any specific intervention, has 2 
been reported to change behaviors of participants (Hawthorne effect
26
). The hypothesis that 3 
the management of PPH would have improved in the control arm is, however, not supported 4 
by the absence of change in the rate of severe PPH between the baseline and trial periods in 5 
this group. 6 
The most plausible explanation of the negative result of this trial is that having a more 7 
accurate assessment of postpartum blood loss is not, by itself, sufficient to change behaviors 8 
of care givers and improve PPH management. Lack of identification of women with excessive 9 
postpartum bleeding is a considerable
 
problem, potentially leading to higher levels of medical 10 
intervention if the bleeding progresses to severe haemorrhage. We designed a strategy to 11 
increase care-givers awareness. The fact
 
that this has not translated into a change in clinical 12 
outcomes
 
probably reflects the complexity of management decisions, which are influenced by 13 
multiple factors such as organization of the delivery ward, and how care givers perceive and 14 
cope with emergencies. 15 
Comparison with other studies 16 
We did not find any other published study assessing the effectiveness of the collector bag.  17 
However we have identified other large multicentre randomised trials in the field of maternal 18 
and child health where a diagnostic or screening test was evaluated without any associated 19 
instructions about the management of abnormal results
27-29
.  None of these trials showed 20 
benefit with the introduction of the test.  In addition Althabe et al have shown that simple 21 
information is not sufficient to impact birth attendants readiness to change
30
. These various 22 
reports suggest that the effect of enhanced diagnostic methods should include an 23 
accompanying protocol of management, and maybe a specific behavioral intervention, which 24 
in effect becomes a “complex intervention”. 25 
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Conclusions and policy implications 1 
The practical implication of these results for high income countries, is that those units which 2 
are using a collector bag (at a cost between 1 and 11 € per bag in Europe) need to reconsider 3 
their practice, and maybe reallocate the resources to other aspects of care. Units which are not 4 
routinely using the bag should keep the same policy.  For resource poor countries positive 5 
results of the use of the “kanga collector” have been reported31.  This needs to be tested in a 6 
randomised design.  In the current context of reported on-going increase in the prevalence of 7 
PPH, further research is needed to develop and test effective strategies to decrease the 8 
prevalence of severe PPH through improvement of management. These will probably be 9 
multifaceted interventions, and in this context, the collector bag may warrant further 10 
investigation. 11 
12 
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« What this paper adds » box 1 
What is already known on this subject 2 
Delay in diagnosis and initial care for postpartum hemorrhage (PPH) has been reported, and 3 
may result from an underestimation of postpartum blood loss, due to the inaccuracy of visual 4 
assessment. A collector bag has been proposed as a useful tool to objectively measure 5 
postpartum blood loss. However, the impact of its use has never been tested. Despite lacking 6 
evidence, the bag is routinely used in a significant proportion of maternity units in Europe. 7 
 8 
What this study adds 9 
Our study suggests that, for western countries, the routine use of a collector bag to objectively 10 
assess postpartum blood loss after vaginal delivery, without specific guideline regarding 11 
threshold and action, does not reduce the incidence of severe PPH. 12 
13 
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Finland: Helsinki University Central Hospital- Vedran Stefanovic; Midwifery Institute of 1 
Helsinki- Veli-Matti Ulander; University central hospital of Turku- Risto Erkkola; University 2 
Hospital of Tampere-Jukka Uotila. France:  Moulin Hospital- Michel Beytout, Catherine 3 
Damouret; University Hospital (Nancy)- Brigitte Guillemain; Antoine Béclère; University 4 
Hospital (Clamart)-Aurélia Chauveaud; Tenon University Hospital (Paris)- Nadia Berkane, 5 
Marie-Christine Chaux; University Hospital (Rouen)- Loic Marpeau, Sabine Sionville; 6 
Villleneuve St Georges Hospital- Patricia Tran van. Hungary: Co-ordination – István Szabó; 7 
Baranya County Hospital (Pécs)-József Bódis; City Hospital (Mosonmagyaróvár)- István 8 
Barcza; Erzsébet Hospital (Sopron)- Károly Péter Csécsei; Petz Aladár Teaching Hospital 9 
(Győr)- Sándor Gardó; Selye János Hospital (Komárom)- László Rokay; Szent Borbála 10 
Hospital (Tatabánya)- Mihály Molnár; University Hospital (Sci. Univ. Pécs)- István Szabó, 11 
Tamás Csermely; Vaszary Kolos Teaching Hospital (Esztergom)- István Berbik. Ireland:  12 
Co-ordination –Reem Akkawi, Fidelma Cavanagh; Coombe Women’s Hospital (Dublin)- 13 
Suzanne Kelly; Our Lady of Lourdes (Drogheda)- Dalia Sikafi, Ann Keating; Cavan General 14 
Hospital- Iram Basit, Marie McCusker; Midland Regional Hospital Mullingar- Mary Corbet. 15 
Italy: Az. SS. Antonio e Biagio e C Arrigo- Enrico Rovetta; Osp di Bassano del Grappa- 16 
Yoram Meir; Osp Civile San Paolo- Antonio Castellano; Osp Civile S Liberatore- Claudio 17 
Angeloni; Osp San Massimo di Penne- Quirino Di Nisio; Pres Osp Di Piove Di Sacco- 18 
Antonino Oro. Netherlands: Co-ordination – Marlies Rijnders, Esteriek de Miranda; St Lucas 19 
Hospital; Bronovo Hospital. Norway: Co-ordination –Bente Rønnes; Sykehuset Innlandet; 20 
Gjovik- Anne Kari Gjestvang, Elham Mahjoob; Sykehuset Innlandet Elverum- Agneta 21 
Stramrud. Portugal: Co-ordination – Maria Fatima Oliveira, Cristina Ferreirinha;  22 
Maternidade Bissaya Barreto (Coimbra)- Ascenção Baía ; Maternidade Daniel de Matos 23 
(Coimbra) - José Portugal; H. S. Marcos (Braga) - Lucília Guerra Sousa: H. S. Joao (Porto)- 24 
Cristina Ferreirinha; Senhora da Oliveira (Guimaraes) - Alice Santos .Spain: Co-ordination -25 
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Sonia Pisa, Sara Herrero; H. Clínic- Enrique Barrau, Jordi Bellart, Isabel Salgado; H. Vall 1 
d'Hebró- Anna Suy; H. Sabadell- Jordi Costa, Maria Grimau; H. Joan XXIII- Ramón Mª 2 
Miralles; H. del Mar- Antoni Payà; H. San Joan de Deu- Sergi Cabré; H. Sant Pau- Marta 3 
Simó; H. Germans Trias- José  Lecumberri. Switzerland: Co-ordination -Irene Hösli, Gideon 4 
Sartorius; Aarau-Monya Todesco; Basel- Gideon Sartorius; Frauenfeld- Verena Geissbühler; 5 
Fribourg- David Stucki, Heidrun Schönberger; Solothurn- Suzanne Zakher; St Gallen- Gero 6 
Drack, Anika Hey-Moonen.7 
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Table 1- Number of maternity units and women in baseline and trial periods by allocation and by country* 
  Maternity units  Women 
Country  Intervention Control  Total % total Baseline period Trial period 
  N N  N (%)  Total Intervention Control Total Intervention Control 
Austria  3 3  1067 3.0 371 219 152 696 359 337 
Belgium  8 8  6013 17.1 1552 728 824 4461 1867 2594 
Denmark  3 3  1657 4.7 507 272 235 1150 562 588 
Finland  2 2  4805 13.7 1347 656 691 3458 1551 1907 
France  3 3  3702 10.6 972 544 428 2730 1351 1379 
Hungary  4 4  2230 6.4 562 268 294 1668 784 884 
Ireland  2 2  3971 11.3 950 300 650 3021 946 2075 
Italy  3 3  926 2.6 196 138 58 730 491 239 
Netherlands  1 1  1084 3.1 301 130 171 783 322 461 
Norway  1 1  668 1.9 143 72 71 525 241 284 
Portugal  2 3  3274 9.3 810 338 472 2464 901 1563 
Spain  4 3  4351 12.4 1595 1097 498 2756 1239 1517 
Switzerland  3 3  1328 3.8 389 175 214 939 423 516 
Total  39 39  35076 100.0 9695 4937 4758 25381 11037 14344 
* Baseline data were unavailable in one maternity unit in the intervention group 
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Table 2- Baseline characteristics of maternity units and individual women by allocation* 
 Intervention 
group 
Control 
group 
Maternity units N=38† N=39 
Rate of caesarean delivery − (%) 
Median  
Interquartile range  
 
21.1 
17.4-26.6 
 
21.7 
14.6-26.0 
>1600 deliveries/yr − no. (%)  20 (52.6) 19 (48.7) 
 
Women 
 
N=4937 
 
N=4758 
Age  − yr 
Mean  
Median  
Interquartile range  
Missing data − no. 
 
29.6±5.4 
30.0 
26-33 
31 
 
29.7± 5.5 
30.0 
26- 33 
23 
Mode of delivery − no. (%) 
Spontaneous vaginal delivery 
Operative vaginal delivery 
 
4104 (83.1) 
  833 (16.9) 
 
4062 (85.4) 
  696 (14.6) 
Induction − no. (%) 1080 (21.9) 1043 (21.9) 
Number of babies − no. (%) 
Single 
Multiple 
Missing data − no. 
 
4833 (98.5) 
  76 (1.5) 
28 
 
4645 (98.6) 
  68 (1.4) 
45 
Birth weight − grams 
Mean 
Median  
Interquartile range  
Missing  data − no. 
 
3315±566.4 
3330 
3020-3660 
26 
 
3349±549.1 
3370 
3050-3690 
29 
Prophylactic uterotonics in 3rd stage − no. (%) 
Missing data – no.  
3527 (71.4) 
0 
3153 (66.3) 
5 
Prostaglandin used after birth − no. (%) 
Missing data – no. 
212 (4.3) 
0 
218 (4.6) 
5 
Manual removal of the placenta − no. (%) 
Missing data – no. 
204 (4.1) 
0 
121 (2.5) 
5 
Severe PPH − no. (%)     60 (1.22)    90 (1.89) 
* Plus-minus values are mean ±SD.  Severe PPH denotes severe Post-Partum Haemorrhage defined by one of the 
following: maternal death, transfusion, plasma expansion, surgery/embolisation, ICU, recombinant factor VII. 
† Baseline data were unavailable in one maternity unit. 
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Table 3- Main outcomes* 
 Intervention 
N=11037 
no. (%) 
Control 
N=14344 
no. (%) 
ICC 
(ρ ) 
Crude odds ratio (95% 
CI) 
Adjusted OR 
(95% CI)† 
Adjusted OR 
(95% CI)‡ 
Primary outcome  
Severe PPH 
 
189 (1.71) 
 
295 (2.06) 
 
0.023 
 
0.83 (0.69-1.00) 
P=0.05 
 
0.83 (0.27-2.60) 
P=0.8 
 
0.82 (0.26-2.53) 
P=0.7 
Secondary outcomes        
Blood transfusion 86 (0.78) 135 (0.94) 0.011 0.83 (0.63-1.68) 
P=0.2 
0.83 (0.35-1.96) 
P=0.8 
0.80 (0.33-1.90) 
P=0.6 
Plasma expander 127 (1.15) 222 (1.55) 0.022 0.74 (0.59-0.92) 
P=0.007 
0.74 (0.20-2.72) 
P=0.7 
0.95 (0.62-1.46) 
P=1.0 
Surgical procedure or 
embolisation 
 50 (0.45)  76 (0.53) 0.012 0.85 (0.60-1.22) 
P=0.9 
0.85 (0.20-3.63) 
P=0.9 
0.78 (0.18-3.40) 
P=0.7 
Manual removal of 
placental 
326 (2.95) 366 (2.55) 0.016 1.16 (1.00-1.35) 
P=0.05 
1.16 (0.76-1.77) 
P=0.5 
1.09 (0.72-1.67) 
P=0.7 
Prostaglandins use 501 (4.54) 766 (5.34) 0.129 0.84 (0.75-0.95) 
P=0.004 
0.84 (0.40-1.77) 
P=0.7 
0.85 (0.40-1.80) 
P=0.7 
* Severe PPH denotes severe Post-Partum Haemorrhage defined by one of the following: maternal death, transfusion, plasma expansion, surgery/embolisation, ICU, 
recombinant factor VII. ICC denotes Intracluster Correlation Coefficient (ρ) 
† Adjusted for clustering (maternity unit) 
‡ Adjusted for clustering (maternity unit), age of mother, prophylactic uterotonics using in the third stage, mode of delivery and birth weight
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 Legends for figures 
Figure 1: Trial flow diagram 
Figure 2: Rate of severe post-partum haemorrhage during baseline and trial periods for each 
maternity unit (Each dot represents one maternity unit. The diagonal line means no change in 
the PPH rate from baseline to trial period)  
Figure 3: Difference in rate of severe post-partum haemorrhage (baseline rate- intervention 
rate) according to compliance with intervention (% of women with measured blood loss) in 
the 38 units in the intervention group during the trial period 
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